Health Condition 1: I462- Cardiac arrest due to underlying cardiac condition
Conditions
Interventions
Intervention1: Nil: Nil
Sponsors
Dr Reddys Laboratories Ltd
Eligibility
Inclusion criteria
Inclusion criteria: 1.Heart failure Patients who have been prescribed with CIDMUS and ejection fraction (EF) value are reported at baseline. 2.Patients of either sex =18 years of age
Exclusion criteria
Exclusion criteria: Patients for whom EF value is not reported at baseline
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. To evaluate the usage of sacubitril/valsartan across different ranges of EF (=40%, 41-49%, =50%) – signifying HF with reduced EF (HFrEF), HF with moderately reduced EF (HFmrEF), & HF with preserved EF (HFpEF), respectively. 2.To understand baseline demographics – patients’ age, gender, body mass index (BMI), systolic blood pressure (SBP), diastolic blood pressure (DBP), comorbid conditions and concomitant medications like beta blocker [BB], mineralocorticoid receptor antagonist [MRA], Sodium-glucose cotransporter-2 [SGLT2] inhibitors and combinations) as monotherapy and/or combination therapy in HF patients on sacubitril/valsartan.Timepoint: 2017 to 2023 (Data will be captured for one consecutive follow-up visit from the baseline visit/index date) | — |
Secondary
| Measure | Time frame |
|---|---|
| • The effect of CIDMUS on change in EF from baseline • Change in SBP, & DBP from baseline to follow up visits • Change in potassium levels from baseline to follow up visit • Average dose & dose titrations of CIDMUS Timepoint: 2017 to 2023 (Data will be captured for one consecutive follow-up visit from the baseline visit/index date) | — |
Countries
India
Contacts
Public ContactDr Rahul Rathod
Dr Reddys Laboratories Limited
Outcome results
None listed